Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
Source: SeekingAlpha
2026-02-26 17:38:27 ET
More on Collegium Pharmaceutical
- Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
- Collegium Pharmaceutical: Buying The Projected Growth For 2026
- Collegium Pharmaceutical, Inc. (COLL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Collegium Pharmaceutical Q4 2025 Earnings Preview
- Collegium Pharmaceutical issues 2026 revenue guidance in line with estimates
Read the full article on Seeking Alpha
For further details see:
Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
Collegium Pharmaceutical Inc.
NASDAQ: COLL
COLL Trading
1.28% G/L:
$37.20 Last:
134,808 Volume:
$36.65 Open:
COLL Latest News
COLL Stock Data
$1,476,390,634
30,817,541
0.71%
106
N/A
Pharmaceuticals
Healthcare
US
Stoughton
